According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “
Separately, Maxim Group reissued a buy rating and set a $16.00 target price on shares of Nephros in a research report on Friday, April 3rd.
Shares of OTCMKTS NEPH opened at $8.39 on Tuesday. The firm has a market cap of $71.16 million, a PE ratio of -15.54 and a beta of 0.85. The company has a 50 day simple moving average of $7.88 and a 200 day simple moving average of $8.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.56 and a quick ratio of 1.86. Nephros has a 1 year low of $4.42 and a 1 year high of $11.35.
Nephros (OTCMKTS:NEPH) last released its earnings results on Wednesday, May 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04). The firm had revenue of $2.53 million for the quarter. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%. As a group, research analysts anticipate that Nephros will post -0.63 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its position in shares of Nephros by 238.0% during the 1st quarter. BlackRock Inc. now owns 8,659 shares of the company’s stock worth $54,000 after buying an additional 6,097 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of Nephros during the 1st quarter worth approximately $251,000. Cowen Prime Services LLC acquired a new stake in shares of Nephros during the 1st quarter worth approximately $975,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Nephros during the 4th quarter worth approximately $1,987,000. Finally, Wexford Capital LP acquired a new stake in shares of Nephros during the 1st quarter worth approximately $21,391,000.
Nephros Company Profile
Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Article: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.